CPIXHIGH SIGNALFINANCIAL10-K

CPIX achieved dramatic 268% revenue growth to $42M while simultaneously improving operating cash flow from negative $612K to positive $4.9M, though net losses increased and cash position declined significantly.

The massive revenue increase combined with positive operating cash flow generation suggests the company's core business operations are gaining significant traction. However, the widening net losses alongside a 36% decline in cash reserves to $11.4M creates a tension between growth momentum and financial sustainability that investors must monitor closely.

Comparing 2026-03-09 vs 2025-03-07View on EDGAR →
FINANCIAL ANALYSIS

CPIX delivered exceptional top-line growth with revenue surging 268% to $42M, driving substantial improvements in working capital metrics including 55% inventory growth and 45% increase in accounts receivable, while remarkably achieving positive operating cash flow of $4.9M versus prior year's negative $612K. However, this growth came at a cost with net losses deepening 46% to -$2.8M and cash reserves declining sharply by 36% to $11.4M, while current liabilities increased 16%. The overall picture suggests a company experiencing rapid business expansion that is generating operational cash but still burning through its balance sheet liquidity, creating both significant opportunity and financial risk for investors.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+905.7%
-$612K$4.9M

Operating cash flow surged 905.7% — exceptional cash generation, highest quality earnings signal.

Revenue
P&L
+268.1%
$11.4M$42.0M

Strong top-line growth of 268.1% — accelerating demand or successful expansion into new markets.

Inventory
Balance Sheet
+55.6%
$4.0M$6.2M

Inventory surged 55.6% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Share Buybacks
Cash Flow
-54.5%
$579K$263K

Buyback activity reduced 54.5% — capital being redeployed elsewhere or cash conservation underway.

Capital Expenditure
Cash Flow
+47.3%
$66K$98K

Capital expenditure jumped 47.3% — major investment cycle underway; assess returns on deployment.

Net Income
P&L
-46.1%
-$1.9M-$2.8M

Net income declined 46.1% — review whether driven by operations, interest costs, or non-recurring items.

Accounts Receivable
Balance Sheet
+44.8%
$11.7M$16.9M

Receivables surged 44.8% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Operating Income
P&L
-42.1%
-$2.0M-$2.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Cash & Equivalents
Balance Sheet
-36.3%
$18.0M$11.4M

Cash declined 36.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Liabilities
Balance Sheet
+16.2%
$31.6M$36.7M

Current liabilities rose 16.2% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-07
ADDED
The aggregate market value of common stock held by non-affiliates as of June 30, 2025 was $ 29,403,593 .
AND SUBSIDIARIES Index Page Number PART I 1 Item 1: Business 1 Item 1A: Risk Factors 36 Item 1B: Unresolved Staff Comments 62 Item 1C.
In addition to these commercial brands, we have announced breakthrough results in a clinical study of our ifetroban product candidate in patients with cardiomyopathy associated with Duchenne muscular dystrophy ( DMD ).
This rare, fatal genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles.
We then completed and submitted a clinical study report to the FDA and began interactions to determine their remaining development requirements.
+7 more — sign up free →
REMOVED
The aggregate market value of common stock held by non-affiliates as of June 30, 2024 was $ 12,234,822 .
AND SUBSIDIARIES Index Page Number PART I 1 Item 1: Business 1 Item 1A: Risk Factors 34 Item 1B: Unresolved Staff Comments 57 Item 1C.
Additionally, we recently completed a Phase II study in patients with cardiomyopathy associated with Duchenne muscular dystrophy ( DMD ), a rare, fatal, genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles.
Next steps for this DMD Program include further data analysis and completion of a full study report in preparation for an end-of-Phase-II meeting with the FDA to determine next steps associated with the product s development and commercialization.
Cumberland has built core competencies for the acquisition, development and commercialization of pharmaceutical products in the U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →